Search clinical trials for: Riociguat (Adempas, BAY63-2521) 1.0 mg

Total 38 results

Bayer

Completed

Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.

Pulmonary Disease, Chronic Obstructive | Hypertension, Pulmonary

Germany
Bayer

Recruiting

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. (RIALTO)

Hypertension, Pulmonary

France, Italy, Korea, Republic of, Poland, Thailand
Bayer
Xcenda, LLC

Active, not recruiting

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (ROAR)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Bayer

Active, not recruiting

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (LEPHT)

Hypertension, Pulmonary | Ventricular Dysfunction, Left

Belgium, France, China, Spain, Japan, United States, Singapore, Canada, Switzerland, Austria, Denmark, Germany, Italy, Australia, Czechia, Netherlands, Poland, United Kingdom
Bayer

Completed

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (EXPERT)

Hypertension, Pulmonary

Turkey, Austria, Czechia, Russian Federation, Slovakia, Switzerland, Italy, Germany, United Kingdom, France, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Sweden, Argentina, Portugal, Saudi Arabia, Austral... and more
Bayer

Completed

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) (JPMS-PAH)

Hypertension, Pulmonary

Japan
Bayer

Completed

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (RESPITE)

Hypertension, Pulmonary

Belgium, United States, Switzerland, Canada, France, Germany, Italy, United Kingdom, Czechia
Bayer

Completed

A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (CAPTURE)

Hypertension, Pulmonary

Japan, Germany, Sweden, Colombia, Turkey, Belgium, Canada
Bayer

Completed

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. (CHEST-1)

Pulmonary Hypertension

Belgium, France, Spain, Turkey, Portugal, Taiwan, Japan, United States, Switzerland, Korea, Republic of, Austria, Canada, China, Denmark, Germany, Russian Federation, Mexico, Argentina, Netherlands, Italy, Poland, United Kingdom, Au... and more
Bayer

Completed

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Scleroderma, Systemic

Netherlands, Belgium, United States, Australia, Hungary, United Kingdom, Canada, Germany, Switzerland, France, Italy, Japan, New Zealand, Turkey, Czechia
Bayer

Completed

Relative Bioavailability Study

Healthy Volunteers

Germany
Bayer

Completed

An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension

Hypertension, Pulmonary

Germany
Bayer

Active, not recruiting

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Hypertension, Pulmonary

Germany
Bayer

Completed

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension (CHEST-2)

Pulmonary Hypertension

Belgium, France, Spain, Turkey, Portugal, Taiwan, Japan, United States, Switzerland, Korea, Republic of, Austria, Canada, China, Denmark, Germany, Mexico, Russian Federation, Argentina, Italy, Poland, Australia, Brazil, Czechia, United... and more
Bayer
Merck Sharp & Dohme LLC

Active, not recruiting

Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (PATENT-CHILD)

Hypertension, Pulmonary

Germany, Turkey, Japan, Italy, Mexico, Poland, Hungary, Taiwan, Colombia
Bayer

Completed

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (JPMS-CTEPH)

Hypertension, Pulmonary

Japan
Bayer

Completed

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) (PATENT-1)

Pulmonary Hypertension

Belgium, France, Spain, China, United States, Turkey, New Zealand, Portugal, Taiwan, Japan, Australia, Singapore, Argentina, Sweden, Switzerland, Mexico, Austria, Thailand, Canada, Denmark, Germany, Israel, Russian Federation, Italy, Korea... and more
Bayer

Completed

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

Hypertension, Pulmonary

United States, Puerto Rico
Bayer

Terminated

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics (HEARTWORK)

Hypertension, Pulmonary | Ventricular Dysfunction, Left

United States
Bayer

Completed

Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator (DIGIT)

Raynaud Disease

Germany
Bayer

Completed

Effect of Riociguat on Bone Metabolism

Pharmacology, Clinical

Germany
Bayer

Completed

Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID

Hypertension, Pulmonary

Germany
Bayer

No longer available

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (EAS)

Hypertension, Pulmonary

Belgium, France, Italy, Spain, United States, Switzerland, Turkey, Portugal, Canada, Sweden, Germany, Austria, Denmark, Mexico, Russian Federation, Colombia, United Kingdom, Netherlands, Japan, Czech Republic
Bayer

Terminated

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (RISE-IIP)

Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

Belgium, Israel, Spain, United States, Switzerland, New Zealand, Greece, Portugal, Japan, Argentina, Canada, Denmark, France, Germany, Russian Federation, Turkey, Colombia, Saudi Arabia, Australia, Italy, United Kingdom
Bayer
Merck Sharp & Dohme LLC

Terminated

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

Cystic Fibrosis

Germany, United States, France, Canada, Belgium, Netherlands, United Kingdom
Bayer

Completed

Relative Bioavailability and Food Effect Study

Pharmacology, Clinical

Germany
Bayer

Completed

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension (PATENT-2)

Hypertension, Pulmonary

Belgium, France, China, Turkey, Portugal, Taiwan, Japan, Singapore, United States, Argentina, Switzerland, Mexico, Austria, Thailand, Canada, Denmark, Germany, Russian Federation, Australia, Italy, Korea, Republic of, Sweden, Poland, United... and more
Bayer

Terminated

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction (DILATE)

Hypertension, Pulmonary | Ventricular Dysfunction, Left

Austria, Germany, Czech Republic
Bayer

Completed

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Clinical Pharmacology

Germany
Danish Headache Center

Not yet recruiting

Effect of Riocigaut on Migraine Attack Induction and Cerebral Vasodilation in Migraine Patients.

Migraine Without Aura

Denmark
Bayer

Completed

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

Clinical Pharmacology

Germany
Bayer

Completed

Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters. (PATENT PLUS)

Pulmonary Hypertension

Spain, New Zealand, Germany, Austria, United States, Poland, Italy, United Kingdom, Czech Republic
Bayer

Completed

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy (REPLACE)

Pulmonary Arterial Hypertension

Belgium, France, Spain, Portugal, Turkey, United States, Germany, Korea, Republic of, Mexico, Austria, Canada, Denmark, Poland, Italy, Greece, Taiwan, Czechia, Netherlands, Japan, Brazil, United Kingdom
Bayer

Withdrawn

Coronary Vasomotor Response After Riociguat Exposure (CORONARIES)

Coronary Artery Disease

United States
International CTEPH Association

Terminated

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

Chronic Thromboembolic Pulmonary Hypertension | CTEPH

Germany, United States, United Kingdom, France
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
Bayer

Completed

Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women

Drug Interactions

Germany
Bayer

Completed

Interaction With HIV Antiretroviral Agents

HIV-DDI

United States

Search clinical trials for: Riociguat (Adempas, BAY63-2521) 1.0 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations